


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



IN RE APPLICATION OF

Art Unit: 1615

WAGNER ET AL.

Examiner: Di Nola Baron, L.

APPLICATION NO: Not Yet Assigned

FILED: Herewith

FOR: SOLID ORAL DOSAGE FORMS OF VALSARTAN

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/202,805 filed May 7, 1999, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6807



Diane Tso
Attorney for Applicants
Reg. No. 46,012

Date: 8/1/01